{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T14:46:51Z","timestamp":1761662811562},"reference-count":20,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2009,11,19]],"date-time":"2009-11-19T00:00:00Z","timestamp":1258588800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2010,2]]},"abstract":"<jats:sec><jats:label \/><jats:p> <jats:italic>Aliment Pharmacol Ther<\/jats:italic>\u2002<jats:bold>31<\/jats:bold>, 502\u2013508<\/jats:p><\/jats:sec><jats:sec><jats:title>Summary<\/jats:title><jats:p><jats:bold>Background\u2002<\/jats:bold> There are few data in the literature regarding the long\u2010term virological follow\u2010up of chronic hepatitis C patients who obtain sustained virological response (SVR) to pegylated interferon (PEG\u2010IFN) and ribavirin therapy.<\/jats:p><jats:p><jats:bold>Aim\u2002<\/jats:bold> To assess the durability of SVR to PEG\u2010IFN and ribavirin therapy during long\u2010term follow\u2010up of chronic hepatitis C patients.<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> We evaluated a cohort of 231 chronic hepatitis C patients who had at least 48\u2003weeks of follow\u2010up after SVR to PEG\u2010IFN and ribavirin treatment. Median duration of follow\u2010up after SVR was 164\u2003weeks, and exceeded 5\u2003years in 30% of the cohort. Patients underwent consistent clinical, biochemical and virological evaluations every 6\u2003months during follow\u2010up.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> Sustained virological response was maintained in 211 patients (91%) while HCV\u2010RNA became positive in two patients (&lt;1%) within 1\u2003year after SVR, and in 18 patients (8%) serum HCV\u2010RNA was transiently positive in at least one follow\u2010up evaluation. Clinical outcome was not significantly different between patients with persistently negative and transiently positive serum HCV\u2010RNA.<\/jats:p><jats:p><jats:bold>Conclusions\u2002<\/jats:bold> Sustained virological response to PEG\u2010IFN and ribavirin is maintained in 99% of patients during long\u2010term follow\u2010up. Late virological relapse occurred within 1\u2003year after SVR and, from a clinical perspective, patients can be considered cured of infection after this period.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1365-2036.2009.04201.x","type":"journal-article","created":{"date-parts":[[2009,11,19]],"date-time":"2009-11-19T17:15:16Z","timestamp":1258650916000},"page":"502-508","source":"Crossref","is-referenced-by-count":39,"title":["Sustained virological response to pegylated interferon and ribavirin is maintained during long\u2010term follow\u2010up of chronic hepatitis C patients"],"prefix":"10.1111","volume":"31","author":[{"given":"E. G.","family":"GIANNINI","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"BASSO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"SAVARINO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"PICCIOTTO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,1,12]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v13.i17.2436"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2001.21905"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840360704"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)06102-5"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020047"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2002.36226"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21064"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2006.00669.x"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2006.02785.x"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2005.00685.x"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22694"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/0168-8278(95)80226-6"},{"issue":"1","key":"e_1_2_6_14_2","first-page":"400A","article-title":"Durability of sustained virological response (SVR) after treatment with peginterferon alfa\u20102a (40KD) (Pegasys) alone or in combination with ribavirin (Copegus): results of an ongoing long\u2010term follow\u2010up study","volume":"40","author":"Swain M","year":"2004","journal-title":"Hepatology"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v13.i17.2467"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2007.03.010"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.78.11.5867-5874.2004"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20518"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.51.1.89"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2003.50350"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.82033-0"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2009.04201.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2036.2009.04201.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T11:25:53Z","timestamp":1698751553000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2009.04201.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1,12]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,2]]}},"alternative-id":["10.1111\/j.1365-2036.2009.04201.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2009.04201.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,1,12]]}}}